The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
Patients must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.
Patients must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.
Age ≥ 18 years.
Histologically or cytologically confirmed locally advanced non small cell lung cancer (NSCLC) stage IIIA non resectable, IIIB or IIIC accordingly to 8th classification TNM, UICC 2015.
Immunotherapy or chemotherapy contra-indicated.
Patients eligible for treatment with concomitant radio-chemotherapy validated by multidisciplinary committee.
Stage I or II NSCLC.
Previously received a treatment with anti-PD1/PDL1, anti-CTLA, or other antineoplastic immunotherapy or chemotherapy for NSCLC.